American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. - Wikidata - awgldk - TriplyDB

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

http://www.wikidata.org/entity/Q35123157

about

Challenges in translating endpoints from trials to observational cohort studies in oncology Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis.Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer Importance of cost-effectiveness and value in cancer care and healthcare policy Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature.International Clinical Trials Day 2014-ancient and modern needs.Current challenges in health economic modeling of cancer therapies: a research inquiry.Ramucirumab: preclinical research and clinical development.Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper.Targeted survival improvements in clinical trials: are you an absolutist or relativist?Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?Tough decisions on essential medicines in 2015.Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study.Impact of industry collaboration on randomised controlled trials in oncology.Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400."New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population.Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.Access to new cancer medicines in Australia: dispelling the myths and informing a public debate.Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research.Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study New Frameworks to Assess Value of Cancer Care: Strengths and Limitations Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial.Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value.American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.BEZ235: When Promising Science Meets Clinical Reality Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis.Second-line outcomes in metastatic colorectal cancer--raising the bar for the high jump rather than the doing the limbo.Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.Adolescent and young adult patients with cancer: a milieu of unique features.The effectiveness of nutritional interventions in malnutrition and cachexia.Overall survival in non-small cell lung cancer-what is clinically meaningful?Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.Chemotherapy for advanced gastric cancer.Early market access of cancer drugs in the EU.Safety and efficacy of targeted agents monotherapy in advanced NSCLC.

P2860

Q26746190-C84F99F3-1220-4701-A69E-33D3D62B1C53 Q26749476-5626ECCE-D5FC-48DE-9CFE-8D08463D39D9 Q26858853-9E303F24-77E9-489C-84F4-8C58DAC0558E Q27318805-6EB26C62-4ABD-4211-9311-3B604769D41E Q28072004-67398B8B-FAD3-4E0F-90E5-8892F02A87D0 Q28078107-9E1C16E4-2C91-4127-B1A6-FFDB4A220D39 Q30249003-277488DF-526B-4CC1-9E43-200526594A2F Q33649540-7378D062-CFB9-4972-9D3F-3C04E114F01D Q33805471-85632745-F614-43BB-A2A4-05F9D70CA1A8 Q34446310-E166B342-D861-4842-A41D-F469E5B2C90E Q35005736-D7CE1E2B-E3F6-4836-A85B-DE59F1E2BB63 Q35084155-D7F1B19C-E999-4B46-B3E7-4E2ABA04730D Q35223735-D10E185E-4F23-4719-9CF2-CD04A9E982E8 Q35606112-C3957D7B-4E30-4F27-8D49-E6CEED1C77D0 Q36174876-7BC0885E-5938-482C-8072-899BDD8FB529 Q36233962-4A5E3472-FFAC-4AB6-B714-139237C29D28 Q36303134-83BAC582-AF62-47C7-9C19-57DABEED2FFD Q36361371-2FF19934-EFBA-4A62-872D-CA5E828194B8 Q36384541-92E20F62-C444-46EE-BE6C-8E35AA97884B Q36402852-B8D0F2A5-11C2-4CF8-AAFF-AFC2B6EE719F Q36553713-35F2A8F9-0100-4DD0-B9BF-506BB65A28F0 Q36774740-2778702A-3EA5-4E14-B5AA-63D33363C5DF Q36782374-4FB3F921-C5F6-494B-956F-2746C5D50C64 Q36883947-00EF1490-B817-4A91-9E47-FEE955FBDFE9 Q37007189-217B4153-47D7-47EB-9DA0-736360BE4880 Q37017054-99C94E05-A995-4F0A-9341-6A45521403CC Q37079932-E8F09CA1-14AC-4285-9B00-3DEE1C3F51E4 Q37135340-965A3D17-3DF8-484E-850B-F57802D71D68 Q37240851-BBDB1F3C-CF51-4F2C-8BEB-0F3B997FFF13 Q37242369-74C8748B-888C-4FF4-A424-3D18A7D1711B Q37275076-60542D65-F566-4635-BEE6-24EACF722613 Q38281831-633712BA-13A5-49EC-A9E1-58F98D64A56C Q38335360-9A86DC9B-40DB-403D-9BF8-7869C8FE387F Q38502885-EE37D355-A340-40F5-B670-BC3B0B6E2A43 Q38531286-36B30932-6013-4046-80E0-A38ADB5212AA Q38549693-3C801267-4078-48E2-8180-C3497B28AADB Q38567540-6F39C82B-4104-45B7-B041-AAE94161D49A Q38604012-CDC1226F-6580-4D90-AD4D-66EA3E866D66 Q38612833-0A8A8861-240A-4EC4-9D07-F48CD8FAB308 Q38630725-8D46EB37-7EFA-4E28-95A5-247F3782326F

P2860

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

http://www.wikidata.org/entity/Q35123157

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

American Society of Clinical O ...... linically meaningful outcomes.

@ast

American Society of Clinical O ...... linically meaningful outcomes.

@en

type

label

American Society of Clinical O ...... linically meaningful outcomes.

@ast

American Society of Clinical O ...... linically meaningful outcomes.

@en

prefLabel

American Society of Clinical O ...... linically meaningful outcomes.

@ast

American Society of Clinical O ...... linically meaningful outcomes.

@en

P1433

Q35123157-781D2683-0673-498E-B099-459E1CF7E232

P1476

Q35123157-AF715B6C-0216-4974-B44A-4B374C19A2F4

P2093

Q35123157-3A8667DE-C286-4B74-A4B5-6034F0753E69

Q35123157-3FE8AB20-D8CD-4AF4-B56E-FEF3385BDFCC

Q35123157-4A06C6EA-79B6-4253-8800-AE28976C12E3

Q35123157-7420466B-31DE-46BA-838D-2B28B6446231

Q35123157-840FED30-B51C-44A2-AC99-BBCF5A7301B1

Q35123157-C0BAE046-085C-4E1F-B505-7B7AFE6127DD

Q35123157-D0DAF3D1-DDE6-4437-829C-930738215763

Q35123157-D71A82F0-DF8A-45CA-8162-12D948137CB6

Q35123157-E316022D-2B3C-40AA-B954-B7A5AB600121

Q35123157-E4BAE37C-5FB5-4055-9682-B6F3E73856CA

P304

Q35123157-1E818569-D6D8-4D7E-9A03-2A2E7FB0154F

P31

Q35123157-38E49F53-3DE6-4F24-B7FD-579B045DFD39

P356

Q35123157-BB2ABE0E-DF37-4E31-BF4F-C885B9C4775A

P407

Q35123157-A919B14C-4483-451F-9EE7-6B5BD97B5995

P433

Q35123157-623D1BEE-8342-491D-9235-9D3037380FA9

P478

Q35123157-7FD8F086-96E0-4377-BBE5-554CFF9C6346

P50

Q35123157-97196B42-107B-4154-92BA-7C9505C8D57E

P577

Q35123157-E7B0E9F5-016B-45FA-BB82-4717B558BD26

P698

Q35123157-C1DCE119-7C34-4185-A175-972F536807B7

P356

JCO.2013.53.8009

P1433

Journal of Clinical Oncology

P1476

American Society of Clinical O ...... linically meaningful outcomes.

@en

P2093

Alan P Venook

http://www.w3.org/2001/XMLSchema#string

Camelia Sima

http://www.w3.org/2001/XMLSchema#string

Daniel Sargent

http://www.w3.org/2001/XMLSchema#string

David S Bernstein

http://www.w3.org/2001/XMLSchema#string

Elizabeth Garrett-Mayer

http://www.w3.org/2001/XMLSchema#string

Emile E Voest

http://www.w3.org/2001/XMLSchema#string

Jordan D Berlin

http://www.w3.org/2001/XMLSchema#string

Lee M Ellis

http://www.w3.org/2001/XMLSchema#string

Lowell E Schnipper

http://www.w3.org/2001/XMLSchema#string

Mithat Gonen

http://www.w3.org/2001/XMLSchema#string

P304

1277-1280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.53.8009

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24638016

http://www.w3.org/2001/XMLSchema#string